Is toxoplasma gondii a trigger of bipolar disorder?

Pathogens

Volumn 6, Issue 1, 2017, Pages

  Del Grande, Claudia ^a   Galli, Luca ^a   Schiavi, Elisa ^a   Dell’Osso, Liliana ^a   Bruschi, Fabrizio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Antipsychotics and mood stabilizers; Bipolar disorder; Dopaminergic pathways; Immunity; Pro inflammatory cytokines; Toxoplasma gondii

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHLORPROMAZINE; CYAMEMAZINE; DAPSONE; DOPAMINE; FLUPHENAZINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HALOPERIDOL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LEVOMEPROMAZINE; LOXAPINE; PALIPERIDONE; PYRIMETHAMINE; RISPERIDONE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRIMETHOPRIM; TUMOR NECROSIS FACTOR; TYROSINE 3 MONOOXYGENASE; UNINDEXED DRUG;

BIPOLAR DISORDER; ENCEPHALITIS; GENETIC POLYMORPHISM; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; NERVOUS SYSTEM INFLAMMATION; NEUROTRANSMISSION; PATHOGENESIS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEROPREVALENCE; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 85009810418     PISSN: None     EISSN: 20760817     Source Type: Journal    
DOI: 10.3390/pathogens6010003     Document Type: Review

References (147)

1. Judd, L.L., Akiskal, H.S., Schettler, P.J., Endicott, J., Leon, A.C., Solomon, D.A., Coryell, W., Maser, J.D., Keller, M.B. Psychosocial disability in the course of bipolar I and II disorders: A prospective, comparative, longitudinal study. Arch. Gen. Psychiatry 2005, 62, 1322-1330.
2. Collins, P.Y., Patel, V., Joestl, S.S., March, D., Insel, T.R., Daar, A.S. Grand challenges in global mental health. Nature 2011, 475, 27-30.
3. Whiteford, H.A., Degenhardt, L., Rehm, J., Baxter, A.J., Ferrari, A.J., Erskine, H.E., Charlson, F.J., Norman, R.E., Flaxman, A.D., Johns, N., et al. Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. Lancet 2013, 382, 1575-1586.
4. Gershon, E.S., Alliey-Rodriguez, N., Liu, C. After GWAS: Searching for genetic risk for schizophrenia and bipolar disorder. Am. J. Psychiatry 2011, 168, 253-256.
5. Kerner, B. Genetics of bipolar disorder. Appl. Clin. Genet. 2014, 7, 33-42.
6. O’Brien, S.M., Scully, P., Scott, L.V., Dinan, T.G. Cytokine profiles in bipolar affective disorder: Focus on acutely ill patients. J. Affect. Disord. 2006, 90, 263-267.
7. Dickerson, F., Stallings, C., Origoni, A., Boronow, J., Yolken, R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 952-955.
8. Ortiz-Domínguez, A., Hernández, M.E., Berlanga, C., Gutiérrez-Mora, D., Moreno, J., Heinze, G., Pavón, L. Immune variations in bipolar disorder: Phasic differences. Bipolar. Disord. 2007, 9, 596-602.
9. Hamdani, N., Doukhan, R., Kurtlucan, O., Tamouza, R., Leboyer, M. Immunity, inflammation, and bipolar disorder: Diagnostic and therapeutic implications. Curr. Psychiatry Rep. 2013, 15, 387.
10. Canetta, S.E., Bao, Y., Co, M.D., Ennis, F.A., Cruz, J., Terajima, M., Shen, L., Kellendonk, C., Schaefer, C.A., Brown, A.S. Serological documentation of maternal influenza exposure and bipolar disorder in adult offspring. Am. J. Psychiatry 2014, 171, 557-563.
11. Muneer, A. Bipolar Disorder: Role of Inflammation and the Development of Disease Biomarkers. Psychiatry Investig. 2016, 13, 18-33.
12. Rosenblat, J.D., McIntyre, R.S. Bipolar Disorder and Inflammation. Psychiatr. Clin. N. Am. 2016, 39, 125-137.
13. Remlinger-Molenda, A., Wojciak, P., Michalak, M., Karczewski, J., Rybakowski, J.K. Selected cytokine profiles during remission in bipolar patients. Neuropsychobiology 2012, 66, 193-198.
14. Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Katsafanas, E., Khushalani, S., Yolken, R. A combined marker of inflammation in individuals with mania. PLoS ONE 2013, 8, e73520.
15. Yolken, R.H., Torrey, E.F. Are some cases of psychosis caused by microbial agents? A review of the evidence. Mol. Psychiatry 2008, 13, 470-479.
16. Yolken, R.H., Dickerson, F.B., Torrey, E.F. Toxoplasma and schizophrenia. Parasite Immunol. 2009, 31, 706-715.
17. Brown, A.S., Derkits, E.J. Prenatal infection and schizophrenia: A review of epidemiologic and translational studies. Am. J. Psychiatry 2010, 167, 261-280.
18. Arias, I., Sorlozano, A., Villegas, E., de Dios Luna, J., McKenney, K., Cervilla, J., Gutierrez, B., Gutierrez, J. Infectious agents associated with schizophrenia: A meta-analysis. Schizophr. Res. 2012, 136, 128-136.
19. Torrey, E.F., Bartko, J.J., Yolken, R.H. Toxoplasma gondii and other risk factors for schizophrenia: An update. Schizophr. Bull. 2012, 38, 642-647.
20. Hamdani, N., Daban-Huard, C., Lajnef, M., Richard, J.R., Delavest, M., Godin, O., Le Guen, E., Vederine, F.E., Lépine, J.P., Jamain, S., et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J. Affect. Disord. 2013, 148, 444-448.
21. Sutterland, A.L., Fond, G., Kuin, A., Koeter, M.W., Lutter, R., van Gool, T., Yolken, R., Szoke, A., Leboyer, M., de Haan, L. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: Systematic review and meta-analysis. Acta Psychiatr. Scand. 2015, 132, 161-179.
22. Montoya, J.G., Liesenfeld, O. Toxoplasmosis. Lancet 2004, 363, 1965-1976.
23. Dubey, J.P., Jones, J.L. Toxoplasma gondii infection in humans and animals in the United States. Int. J. Parasitol. 2008, 38, 1257-1278.
24. Robert-Gangneux, F., Dardé, M.L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin. Microbiol. Rev. 2012, 25, 264-296.
25. Jones, J.L., Dargelas, V., Roberts, J., Press, C., Remington, J.S., Montoya, J.G. Risk factors for Toxoplasma gondii infection in the United States. Clin. Infect. Dis. 2009, 49, 878-884.
26. Weiss, L.M., Dubey, J.P. Toxoplasmosis: A history of clinical observations. Int. J. Parasitol. 2009, 39, 895-901.
27. Bahia-Oliveira, L.M., Jones, J.L., Azevedo-Silva, J., Alves, C.C., Oréfice, F., Addiss, D.G. Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg. Infect. Dis. 2003, 9, 55-62.
28. Bamne, M., Wood, J., Chowdari, K., Watson, A.M., Celik, C., Mansour, H., Klei, L., Gur, R.C., Bradford, L.D., Calkins, M.E., et al. Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure. Schizophr. Bull. 2012, 38, 1149-1154.
29. Remington, J.S., McLeod, R., Thulliez, P., Desmonts, G. Toxoplasmosis. In Infectious Diseases of the Fetus and Newborn Infant, 5th ed., Remington, J.S., Klein, J., Eds., WB Saunders: Philadelphia, PA, USA, 2001, pp. 205-346.
30. Kaye, A. Toxoplasmosis: Diagnosis, treatment, and prevention in congenitally exposed infants. J. Pediatr. Health Care 2011, 25, 355-364.
31. Block, M.L., Hong, J. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog. Neurobiol. 2005, 76, 77-98.
32. Bergink, V., Gibney, S.M., Drexhage, H.A. Autoimmunity, inflammation, and psychosis: A search for peripheral markers. Biol. Psychiatry 2014, 75, 324-331.
33. Havlícek, J., Gasová, Z.G., Smith, A.P., Zvára, K., Flegr, J. Decrease of psychomotor performance in subjects with latent ‘asymptomatic’ toxoplasmosis. Parasitology 2001, 122, 515-520.
34. Flegr, J., Zitková, S., Kodym, P., Frynta, D. Induction of changes in human behaviour by the parasitic protozoan Toxoplasma gondii. Parasitology 1996, 113, 49-54.
35. Flegr, J., Preiss, M., Klose, J., Havlícek, J., Vitáková, M., Kodym, P. Decreased level of psychobiological factor novelty seeking and lower intelligence in men latently infected with the protozoan parasite Toxoplasma gondii Dopamine, a missing link between schizophrenia and toxoplasmosis? Biol. Psychol. 2003, 63, 253-268.
36. Hinze-Selch, D., Däubener, W., Erdag, S., Wilms, S. The diagnosis of a personality disorder increases the likelihood for seropositivity to Toxoplasma gondii in psychiatric patients. Folia Parasitol. 2010, 57, 129-135.
37. Flegr, J. Effects of Toxoplasma on human behavior. Schizophr. Bull. 2007, 33, 757-760.
38. Flegr, J. Influence of latent Toxoplasma infection on human personality, physiology and morphology: Pros and cons of the Toxoplasma-human model in studying the manipulation hypothesis. J. Exp. Biol. 2013, 216, 127-133.
39. Cook, T.B., Brenner, L.A., Cloninger, C.R., Langenberg, P., Igbide, A., Giegling, I., Hartmann, A.M., Konte, B., Friedl, M., Brundin, L., et al. “Latent” infection with Toxoplasma gondii: Association with trait aggression and impulsivity in healthy adults. J. Psychiatr. Res. 2015, 60, 87-94.
40. Novotná, M., Hanusova, J., Klose, J., Preiss, M., Havlicek, J., Roubalová, K., Flegr, J. Probable neuroimmunological link between Toxoplasma and cytomegalovirus infections and personality changes in the human host. BMC. Infect. Dis. 2005, 5, 54.
41. Berdoy, M., Webster, J.P., Macdonald, D.W. Fatal attraction in rats infected with Toxoplasma gondii. Proc. Biol. Sci. 2000, 267, 1591-1594.
42. Vyas, A., Kim, S.K., Giacomini, N., Boothroyd, J.C., Sapolsky, R.M. Behavioral changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odors. Proc. Natl. Acad. Sci. USA 2007, 104, 6442-6447.
43. Gulinello, M., Acquarone, M., Kim, J.H., Spray, D.C., Barbosa, H.S., Sellers, R., Tanowitz, H.B., Weiss, L.M. Acquired infection with Toxoplasma gondii in adult mice results in sensorimotor deficits but normal cognitive behavior despite widespread brain pathology. Microbes. Infect. 2010, 12, 528-537.
44. Gatkowska, J., Wieczorek, M., Dziadek, B., Dzitko, K., Dlugonska, H. Behavioral changes in mice caused by Toxoplasma gondii invasion of brain. Parasitol. Res. 2012, 111, 53-58.
45. Vyas, A. Mechanisms of Host Behavioral Change in Toxoplasma gondii Rodent Association. PLoS Pathog. 2015, 11, e1004935.
46. Amminger, G.P., McGorry, P.D., Berger, G.E., Wade, D., Yung, A.R., Phillips, L.J., Harrigan, S.M., Francey, S.M., Yolken, R.H. Antibodies to infectious agents in individuals at ultra-high risk for psychosis. Biol. Psychiatry 2007, 61, 1215-1217.
47. Fabiani, S., Pinto, B., Bonuccelli, U., Bruschi, F. Neurobiological studies on the relationship between toxoplasmosis and neuropsychiatric diseases. J. Neurol. Sci. 2015, 351, 3-8.
48. Arling, T.A., Yolken, R.H., Lapidus, M., Langenberg, P., Dickerson, F.B., Zimmerman, S.A., Balis, T., Cabassa, J.A., Scrandis, D.A., Tonelli, L.H., et al. Toxoplasma gondii antibody titers and history of suicide attempts in patients with recurrent mood disorders. J. Nerv. Ment. Dis. 2009, 197, 905-908. [PubMed
49. Ling, V.J., Lester, D., Mortensen, P.B., Langenberg, P.W., Postolache, T.T. Toxoplasma gondii seropositivity and suicide rates in women. J. Nerv. Ment. Dis. 2011, 199, 440-444.
50. Okusaga, O., Langenberg, P., Sleemi, A., Vaswani, D., Giegling, I., Hartmann, A.M., Konte, B., Friedl, M., Groer, M.W., Yolken, R.H., et al. Toxoplasma gondii antibody titers and history of suicide attempts in patients with schizophrenia. Schizophr. Res. 2011, 133, 150-155.
51. Pedersen, M.G., Mortensen, P.B., Norgaard-Pedersen, B., Postolache, T.T. Toxoplasma gondii infection and self-directed violence in mothers. Arch. Gen. Psychiatry 2012, 69, 1123-1130.
52. Alvarado-Esquivel, C., Sánchez-Anguiano, L.F., Arnaud-Gil, C.A., López-Longoria, J.C., Molina-Espinoza, L.F., Estrada-Martínez, S., Liesenfeld, O., Hernández-Tinoco, J., Sifuentes-Álvarez, A., Salas-Martínez, C. Toxoplasma gondii infection and suicide attempts: A case-control study in psychiatric outpatients. J. Nerv. Ment. Dis. 2013, 201, 948-952.
53. Torrey, E.F., Bartko, J.J., Lun, Z.R., Yolken, R.H. Antibodies to Toxoplasma gondii in patients with schizophrenia: A meta-analysis. Schizophr. Bull. 2007, 33, 729-736.
54. Dickerson, F., Stallings, C., Origoni, A., Katsafanas, E., Schweinfurth, L., Savage, C., Khushalani, S., Yolken, R. Antibodies to Toxoplasma gondii and cognitive functioning in schizophrenia, bipolar disorder, and nonpsychiatric controls. J. Nerv. Ment. Dis. 2014, 202, 589-593.
55. Hamdani, N., Daban-Huard, C., Lajnef, M., Gadel, R., Le Corvoisier, P., Delavest, M., Carde, S., Lépine, J.P., Jamain, S., Houenou, J., et al. Cognitive deterioration among bipolar disorder patients infected by Toxoplasma gondii is correlated to interleukin 6 levels. J. Affect. Disord. 2015, 179, 161-166.
56. Pearce, B.D., Kruszon-Moran, D., Jones, J.L. The relationship between Toxoplasma gondii infection and mood disorders in the third National Health and Nutrition Survey. Biol. Psychiatry 2012, 72, 290-295.
57. Delgado García, G., Rodríguez Perdomo, E. Reactivity of toxoplasmin intradermal test in neurotic and manic-depressive patients. Rev. Cubana Med. Trop. 1980, 32, 35-39.
58. Tedla, Y., Shibre, T., Ali, O., Tadele, G., Woldeamanuel, Y., Asrat, D., Aseffa, A., Mihret, W., Abebe, M., Alem, A. Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: A case-control study. Ethiop. Med. J. 2011, 49, 211-220.
59. Cetinkaya, Z., Yazar, S., Gecici, O., Namli, M.N. Anti-Toxoplasma gondii antibodies in patients with schizophrenia-preliminary findings in a Turkish sample. Schizophr. Bull. 2007, 33, 789-791.
60. Hamidinejat, H., Ghorbanpoor, M., Hosseini, H., Alavi, S.M., Nabavi, L., Jalali, M.H., Borojeni, M.P., Jafari, H., Mohammadaligol, S. Toxoplasma gondii infection in first-episode and inpatient individuals with schizophrenia. Int. J. Infect. Dis. 2010, 14, e978-e981.
61. Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Katsafanas, E., Khushalani, S., Yolken, R. Antibodies to Toxoplasma gondii in individuals with mania. Bipolar. Disord. 2014, 16, 129-136.
62. Duffy, A.R., Beckie, T.M., Brenner, L.A., Beckstead, J.W., Seyfang, A., Postolache, T.T., Groer, M.W. Relationship between Toxoplasma gondii andMood Disturbance inWomen Veterans.Mil. Med. 2015, 180, 621-625.
63. Khademvatan, S., Khajeddin, N., Izadi, S., Saki, J. Study of Toxoplasma gondii Infection in Patients with Bipolar Disorder. J. Med. Sci. 2013, 13, 215-220.
64. Del Grande, C., Contini, C., Schiavi, E., Rutigliano, G., Maritati, M., Seraceni, S., Pinto, B., Dell’Osso, L., Bruschi, F. Bipolar DisorderWith Psychotic Features and Ocular Toxoplasmosis. A Possible Pathogenetic Role of the Parasite? J. Nerv. Ment. Dis. 2016.
65. Mortensen, P.B., Nørgaard-Pedersen, B., Waltoft, B.L., Sørensen, T.L., Hougaard, D., Yolken, R.H. Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophr. Bull. 2007, 33, 741-744.
66. Blomström, Å., Karlsson, H., Gardner, R., Jörgensen, L., Magnusson, C., Dalman, C. Associations Between Maternal Infection During Pregnancy, Childhood Infections, and the Risk of Subsequent Psychotic Disorder-A Swedish Cohort Study of Nearly 2 Million Individuals. Schizophr. Bull. 2016, 42, 125-133.
67. Brown, A.S., Schaefer, C.A., Quesenberry, C.P., Liu, L., Jr., Babulas, V.P., Susser, E.S. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am. J. Psychiatry 2005, 162, 767-773.
68. Mortensen, P.B., Pedersen, C.B., McGrath, J.J., Hougaard, D.M., Nørgaard-Petersen, B., Mors, O., Børglum, A.D., Yolken, R.H. Neonatal antibodies to infectious agents and risk of bipolar disorder: A population-based case-control study. Bipolar. Disord. 2011, 13, 624-629.
69. Freedman, D., Bao, Y., Shen, L., Schaefer, C.A., Brown, A.S. Maternal T. gondii, offspring bipolar disorder and neurocognition. Psychiatry Res. 2016, 243, 382-389.
70. Xiao, J., Buka, S.L., Cannon, T.D., Suzuki, J., Viscidi, R.P., Torrey, E.F., Yolken, R.H. Serological pattern consistent with infection with type I Toxoplasma gondii in mothers and risk of psychosis among adult offspring. Microbes Infect. 2009, 11, 1011-1018.
71. Coccaro, E.F., Lee, R., Groer, M.W., Can, A., Coussons-Read, M., Postolache, T.T. Toxoplasma gondii infection: Relationship with aggression in psychiatric subjects. Clin. Psychiatry 2016, 77, 334-341.
72. Lester, D. Predicting European suicide rates with physiological indices. Psychol. Rep. 2010, 107, 713-714.
73. Zhang, Y., Träskman-Bendz, L., Janelidze, S., Langenberg, P., Saleh, A., Constantine, N., Okusaga, O., Bay-Richter, C., Brundin, L., Postolache, T.T. Toxoplasma gondii immunoglobulin G antibodies and nonfatal suicidal self-directed violence. J. Clin. Psychiatry 2012, 73, 1069-1076.
74. Wang, H.L., Wang, G.H., Li, Q.Y., Shu, C., Jiang, M.S., Guo, Y. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr. Scand. 2006, 114, 40-48.
75. Halonen, S.K., Lyman, W.D., Chiu, F.C. Growth and development of Toxoplasma gondii in human neurons and astrocytes. J. Neuropathol. Exp. Neurol. 1996, 55, 1150-1156.
76. Cotter, D.R., Pariante, C.M., Everall, I.P. Glial cell abnormalities in major psychiatric disorders: The evidence and implications. Brain Res. Bull. 2001, 55, 585-595.
77. Konradt, C., Ueno, N., Christian, D.A., Delong, J.H., Pritchard, G.H., Herz, J., Bzik, D.J., Koshy, A.A., McGavern, D.B., Lodoen, M.B., et al. Endothelial cells are a replicative niche for entry of Toxoplasma gondii to the central nervous system. Nat. Microbiol. 2016, 1, 16001.
78. Da Silva, R.C., Langoni, H. Toxoplasma gondii: Host-parasite interaction and behavior manipulation. Parasitol. Res. 2009, 105, 893e8.
79. Courret, N., Darche, S., Sonigo, P., Milon, G., Buzoni-Gâtel, D., Tardieux, I. CD11c-and CD11b-expressing mouse leukocytes transport single Toxoplasma gondii tachyzoites to the brain. Blood 2006, 107, 309-316.
80. Melzer, T.C., Cranston, H.J., Weiss, L.M., Halonen, S.K. Host Cell Preference of Toxoplasma gondii Cysts in Murine Brain: A Confocal Study. J. Neuroparasitol. 2010, 1, N100505.
81. Berenreiterová, M., Flegr, J., Kubˇena, A.A., Nˇemec, P. The distribution of Toxoplasma gondii cysts in the brain of a mouse with latent toxoplasmosis: Implications for the behavioral manipulation hypothesis. PLoS ONE 2011, 6, e28925.
82. McConkey, G.A., Martin, H.L., Bristow, G.C., Webster, J.P. Toxoplasma gondii infection and behaviour—location, location, location? J. Exp. Biol. 2013, 216, 113-119.
83. Mitra, R., Sapolsky, R.M., Vyas, A. Toxoplasma gondii infection induces dendritic retraction in basolateral amygdala accompanied by reduced corticosterone secretion. Dis. Model. Mech. 2013, 6, 516-520.
84. Dubey, J.P., Ferreira, L.R., Alsaad, M., Verma, S.K., Alves, D.A., Holland, G.N., McConkey, G.A. Experimental Toxoplasmosis in Rats Induced Orally with Eleven Strains of Toxoplasma gondii of Seven Genotypes: Tissue Tropism, Tissue Cyst Size, Neural Lesions, Tissue Cyst Rupture without Reactivation, and Ocular Lesions. PLoS ONE 2016, 11, e0156255.
85. Coccaro, E.F., Sripada, C.S., Yanowitch, R.N., Phan, K.L. Corticolimbic function in impulsive aggressive behavior. Biol. Psychiatry 2011, 69, 1153-1159.
86. Hermes, G., Ajioka, J.W., Kelly, K.A., Mui, E., Roberts, F., Kasza, K., Mayr, T., Kirisits, M.J., Wollmann, R., Ferguson, D.J., et al. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J. Neuroinflamm. 2008, 5, 48.
87. Torrey, E.F., Yolken, R.H. Toxoplasma gondii and schizophrenia. Emerg. Infect. Dis. 2003, 9, 1375-1380.
88. Coccaro, E.F., Lee, R., Kavoussi, R.J. Aggression, suicidality, and intermittent explosive disorder: Serotonergic correlates in personality disorder and healthy control subjects. Neuropsychopharmacology 2010, 35, 435-444.
89. Coccaro, E.F., Lee, R., Vezina, P. Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects. J. Psychiatr. Res. 2013, 47, 1247-1253.
90. Flegr, J. How and why Toxoplasma makes us crazy. Trends Parasitol. 2013, 29, 156-163.
91. Prandovszky, E., Gaskell, E., Martin, H., Dubey, J.P., Webster, J.P., McConkey, G.A. The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. PLoS ONE 2011, 6, e23866.
92. Gaskell, E.A., Smith, J.E., Pinney, J.W., Westhead, D.R., McConkey, G.A. A unique dual activity amino acid hydroxylase in Toxoplasma gondii. PLoS ONE 2009, 4, e4801.
93. Strobl, J.S., Goodwin, D.G., Rzigalinski, B.A., Lindsay, D.S. Dopamine stimulates propagation of Toxoplasma gondii tachyzoites in human fibroblast and primary neonatal rat astrocyte cell cultures. J. Parasitol. 2012, 98, 1296-1299.
94. Stibbs, H.H. Changes in brain concentrations of catecholamines and indoleamines in Toxoplasma gondii infected mice. Ann. Trop. Med. Parasitol. 1985, 79, 153-157.
95. Fabiani, S., Pinto, B., Bruschi, F. Toxoplasmosis and neuropsychiatric disease: Can serological studies establish a clear relationship? Neurol. Sci. 2013, 34, 417-425.
96. Cox, D., Chan, M.K., Bahn, S. The potential of immune biomarkers to advance personalizedmedicine approaches for schizophrenia. J. Nerv. Ment. Dis. 2015, 203, 393-399.
97. Janelidze, S., Mattei, D., Westrin, Å., Träskman-Bendz, L., Brundin, L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain. Behav. Immun. 2011, 25, 335-339.
98. Lindqvist, D., Janelidze, S., Hagell, P., Erhardt, S., Samuelsson, M., Minthon, L., Hansson, O., Björkqvist, M., Träskman-Bendz, L., Brundin, L. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol. Psychiatry 2009, 66, 287-292.
99. Munkholm, K., Braüner, J.V., Kessing, L.V., Vinberg, M. Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. J. Psychiatr. Res. 2013, 47, 1119-1133.
100. Rosenblat, J.D., Cha, D.S., Mansur, R.B., McIntyre, R.S. Inflamed moods: A review of the interactions between inflammation and mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 53, 23-34.
101. Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., Pollmächer, T. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 2001, 58, 445-452.
102. Raison, C.L., Capuron, L., Miller, A.H. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends. Immunol. 2006, 27, 24-31.
103. Harrison, N.A., Brydon, L., Walker, C., Gray, M.A., Steptoe, A., Critchley, H.D. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol. Psychiatry 2009, 66, 407-414.
104. Eisenberger, N.I., Berkman, E.T., Inagaki, T.K., Rameson, L.T., Mashal, N.M., Irwin, M.R. Inflammation-induced anhedonia: Endotoxin reduces ventral striatum responses to reward. Biol. Psychiatry 2010, 68, 748-754.
105. Brietzke, E., Stertz, L., Fernandes, B.S., Kauer-Sant’anna, M., Mascarenhas, M., Escosteguy Vargas, A., Chies, J.A., Kapczinski, F. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord. 2009, 116, 214-217.
106. Söderlund, J., Olsson, S.K., Samuelsson, M., Walther-Jallow, L., Johansson, C., Erhardt, S., Landén, M., Engberg, G. Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J. Psychiatry Neurosci. 2011, 36, 114-118.
107. Bai, Y.M., Su, T.P., Tsai, S.J., Wen-Fei, C., Li, C.T., Pei-Chi, T., Mu-Hong, C. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J. Affect. Disord. 2014, 166, 187-192.
108. Boufidou, F., Nikolaou, C., Alevizos, B., Liappas, I.A., Christodoulou, G.N. Cytokine production in bipolar affective disorder patients under lithium treatment. J. Affect. Disord. 2004, 82, 309-313.
109. Kim, Y.K., Jung, H.G., Myint, A.M., Kim, H., Park, S.H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 2007, 104, 91-95.
110. Guloksuz, S., Cetin, E.A., Cetin, T., Deniz, G., Oral, E.T., Nutt, D.J. Cytokine levels in euthymic bipolar patients. J. Affect. Disord. 2010, 126, 458-462.
111. Goldstein, B.I., Kemp, D.E., Soczynska, J.K., McIntyre, R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature. J. Clin. Psychiatry 2009, 70, 1078-1790.
112. Kapczinski, F., Kauer-Sant’Anna, M., Andreazza, A.C., Bond, D.J., Lam, R.W., Young, L.T., Yatham, L.N. Brain-derived neurotrophic factor and inflammatory markers in patients with early-vs. late-stage bipolar disorder. Int. J. Neuropsychopharmacol. 2009, 12, 447-458.
113. Hinze-Selch, D., Däubener, W., Eggert, L., Erdag, S., Stoltenberg, R., Wilms, S. A controlled prospective study of Toxoplasma gondii infection in individuals with schizophrenia: Beyond seroprevalence. Schizophr. Bull. 2007, 33, 782-788.
114. Myint, A.M., Schwarz, M.J., Verkerk, R., Mueller, H.H., Zach, J., Scharpé, S., Steinbusch, H.W., Leonard, B.E., Kim, Y.K. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients. Brain. Behav. Immun. 2011, 25, 1576-1581.
115. Miller, C.L., Llenos, I.C., Dulay, J.R., Weis, S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006, 16, 1073-1074.
116. Olsson, S.K., Samuelsson, M., Saetre, P., Lindström, L., Jönsson, E.G., Nordin, C., Engberg, G., Erhardt, S., Landén, M. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J. Psychiatry Neurosci. 2010, 35, 195-199.
117. Johansson, A.S., Owe-Larsson, B., Asp, L., Kocki, T., Adler, M., Hetta, J., Gardner, R., Lundkvist, G.B., Urbanska, E.M., Karlsson, H. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: Cytokine challenge increases production of 3-hydroxykynurenine. J. Psychiatr. Res. 2013, 47, 1815-1823.
118. Lim, A., Kumar, V., Hari Dass, S.A., Vyas, A. Toxoplasma gondii infection enhances testicular steroidogenesis in rats. Mol. Ecol. 2013, 22, 102-110.
119. Flegr, J., Lindová, J., Kodym, P. Sex-dependent toxoplasmosis-associated differences in testosterone concentration in humans. Parasitology 2008, 135, 427-431.
120. Carter, C.S., Bullmore, E.T., Harrison, P. Is there a flame in the brain in psychosis? Biol. Psychiatry 2014, 75, 258-259.
121. Benros, M.E., Nielsen, P.R., Nordentoft, M., Eaton, W.W., Dalton, S.O., Mortensen, P.B. Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study. Am. J. Psychiatry 2011, 168, 1303-1310.
122. Benros, M.E., Eaton, W.W., Mortensen, P.B. The epidemiologic evidence linking autoimmune diseases and psychosis. Biol. Psychiatry 2014, 75, 300-306.
123. Monji, A., Kato, T.A., Mizoguchi, Y., Horikawa, H., Seki, Y., Kasai, M., Yamauchi, Y., Yamada, S., Kanba, S. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42, 115-121.
124. Meyer, U. Developmental neuroinflammation and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42, 20-34.
125. Ludvigsson, J.F., Reutfors, J., Osby, U., Ekbom, A., Montgomery, S.M. Coeliac disease and risk of mood disorders-a general population-based cohort study. J. Affect. Disord. 2007, 99, 117-126.
126. Benros, M.E., Waltoft, B.L., Nordentoft, M., Ostergaard, S.D., Eaton, W.W., Krogh, J., Mortensen, P.B. Autoimmune diseases and severe infections as risk factors for mood disorders: A nationwide study. JAMA Psychiatry 2013, 70, 812-820.
127. Avramopoulos, D., Pearce, B.D., McGrath, J., Wolyniec, P., Wang, R., Eckart, N., Hatzimanolis, A., Goes, F.S., Nestadt, G., Mulle, J., et al. Infection and inflammation in schizophrenia and bipolar disorder: A genome wide study for interactions with genetic variation. PLoS ONE 2015, 10, e0116696.
128. De Berardis, D., Conti, C.M., Campanella, D., Carano, A., Scali, M., Valchera, A., Serroni, N., Pizzorno, A.M., D’Albenzio, A., Fulcheri, M., et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int. J. Immunopathol. Pharmacol. 2008, 21, 319-324.
129. Singh, B., Chaudhuri, T.K. Role of C-reactive protein in schizophrenia: An overview. Psychiatry Res. 2014, 216, 277-285.
130. Oliveira, J., Kazma, R., Le Floch, E., Bennabi, M., Hamdani, N., Bengoufa, D., Dahoun, M., Manier, C., Bellivier, F., Krishnamoorthy, R., et al. Toxoplasma gondii exposure may modulate the influence of TLR2 genetic variation on bipolar disorder: A gene-environment interaction study. Int. J. Bipolar. Disord. 2016, 4, 11.
131. Schröder, N.W., Schumann, R.R. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect. Dis. 2005, 5, 156-164.
132. van Well, G.T., Sanders, M.S., Ouburg, S., Kumar, V., van Furth, A.M., Morré, S.A. Single nucleotide polymorphisms in pathogen recognition receptor genes are associated with susceptibility to meningococcal meningitis in a pediatric cohort. PLoS ONE 2013, 8, e64252.
133. Oliveira, J., Busson, M., Etain, B., Jamain, S., Hamdani, N., Boukouaci, W., Amokrane, K., Bennabi, M., Le Guen, E., Dargél, A.A., et al. Polymorphism of Toll-like receptor 4 gene in bipolar disorder. J. Affect. Disord. 2014, 152-154, 395-402.
134. Oliveira, J., Hamdani, N., Busson, M., Etain, B., Bennabi, M., Amokrane, K., Boukouaci, W., Fortier, C., Marzais, F., Bengoufa, D., et al. Association between toll-like receptor 2 gene diversity and early-onset bipolar disorder. J. Affect. Disord. 2014, 165, 135-141.
135. Oliveira, J., Hamdani, N., Etain, B., Bennabi, M., Boukouaci, W., Amokrane, K., Fortier, C., Marzais, F., Bengoufa, D., Bellivier, F., et al. Genetic association between a ‘standing’ variant of NOD2 and bipolar disorder. Immunobiology 2014, 219, 766-771.
136. Oliveira, J., Etain, B., Lajnef, M., Hamdani, N., Bennabi, M., Bengoufa, D., Sundaresh, A., Chaabane, A.B., Bellivier, F., Henry, C., et al. Combined effect of TLR2 gene polymorphism and early life stress on the age at onset of bipolar disorders. PLoS ONE 2015, 10, e0119702.
137. Leweke, F.M., Gerth, C.W., Koethe, D., Klosterkötter, J., Ruslanova, I., Krivogorsky, B., Torrey, E.F., Yolken, R.H. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2004, 254, 4-8.
138. Jones-Brando, L., Torrey, E.F., Yolken, R.H. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr. Res. 2003, 62, 237-244.
139. Webster, J.P., Lamberton, P.H., Donnelly, C.A., Torrey, E.F. Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii’s ability to alter host behaviour. Proc. Biol. Sci. 2006, 273, 1023-1030.
140. Pezzella, N., Bouchot, A., Bonhomme, A., Pingret, L., Klein, C., Burlet, H., Balossier, G., Bonhomme, P., Pinon, J.M. Involvement of calcium and calmodulin in Toxoplasma gondii tachyzoite invasion. Eur. J. Cell Biol. 1997, 74, 92-101.
141. Johannessen, C.U. Mechanisms of action of valproate: A commentatory. Neurochem. Int. 2000, 37, 103-110.
142. Fond, G., Macgregor, A., Tamouza, R., Hamdani, N., Meary, A., Leboyer, M., Dubremetz, J.F. Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. Eur. Arch. Psychiatry Clin. Neurosci. 2014, 264, 179-183.
143. Goodwin, D.G., Strobl, J.S., Lindsay, D.S. Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures. J. Parasitol. 2011, 97, 148-151.
144. Goodwin, D.G., Strobl, J., Mitchell, S.M., Zajac, A.M., Lindsay, D.S. Evaluation of the mood-stabilizing agent valproic acid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice. J. Parasitol. 2008, 94, 555-557.
145. Fond, G., Boyer, L., Gaman, A., Laouamri, H., Attiba, D., Richard, J.R., Delavest, M., Houenou, J., Le Corvoisier, P., Charron, D., et al. Treatment with anti-toxoplasmic activity (TATA) for Toxoplasma positive patients with bipolar disorders or schizophrenia: A cross-sectional study. J. Psychiatr. Res. 2015, 63, 58-64.
146. Selle, V., Schalkwijk, S., Vázquez, G.H., Baldessarini, R.J. Treatments for acute bipolar depression: Meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 2014, 47, 43-52.
147. Musetti, L., Del Grande, C., Marazziti, D., Dell’Osso, L. Treatment of bipolar depression. CNS Spectr. 2013, 18, 177-187.